US Stock MarketDetailed Quotes
SUPN Supernus Pharmaceuticals
- 36.570
- -0.420-1.14%
Close Nov 29 13:00 ET
- 36.570
- 0.0000.00%
Post 17:01 ET
2.02BMarket Cap34.27P/E (TTM)
37.050High36.150Low223.86KVolume36.910Open36.990Pre Close8.19MTurnover0.47%Turnover Ratio1828.50P/E (Static)55.22MShares39.37052wk High2.01P/B1.75BFloat Cap25.53052wk Low--Dividend TTM47.76MShs Float61.250Historical High--Div YieldTTM2.43%Amplitude4.300Historical Low36.576Avg Price1Lot Size
Supernus Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 14.17%175.69M | 24.17%168.33M | -6.58%143.64M | -8.95%607.52M | -1.80%164.31M | -13.24%153.88M | -20.28%135.56M | 0.82%153.76M | 15.09%667.24M | 5.20%167.33M |
| Operating revenue | 14.17%175.69M | 24.17%168.33M | -6.58%143.64M | -8.95%607.52M | -1.80%164.31M | -13.24%153.88M | -20.28%135.56M | 0.82%153.76M | 15.09%667.24M | 5.20%167.33M |
| Cost of revenue | -10.30%17.58M | -15.05%17.92M | -30.48%16.31M | -3.95%83.78M | -14.49%19.63M | -24.26%19.6M | 3.10%21.09M | 30.83%23.46M | 16.20%87.22M | 35.07%22.95M |
| Gross profit | 17.74%158.11M | 31.39%150.41M | -2.28%127.34M | -9.70%523.74M | 0.22%144.69M | -11.35%134.28M | -23.48%114.47M | -3.17%130.3M | 14.92%580.02M | 1.63%144.37M |
| Operating expense | -6.57%118.28M | 0.71%132.2M | 3.79%131.58M | -4.50%510.34M | 11.79%125.7M | -16.99%126.6M | -4.54%131.27M | -3.92%126.78M | 25.68%534.4M | -16.61%112.44M |
| Selling and administrative expenses | -15.66%69.75M | -1.01%85.9M | 1.07%86.52M | -10.83%336.36M | 9.88%81.28M | -26.37%82.7M | -13.63%86.78M | -5.37%85.6M | 23.78%377.22M | -27.29%73.97M |
| -Selling and marketing expense | -4.33%54.33M | -1.82%58.8M | 4.08%59.57M | -14.42%229.19M | 15.18%55.28M | -33.74%56.79M | -18.60%59.89M | -5.43%57.23M | --267.79M | --47.99M |
| -General and administrative expense | -40.48%15.42M | 0.79%27.1M | -5.00%26.95M | -2.06%107.18M | 0.09%26.01M | -2.61%25.92M | -0.03%26.89M | -5.27%28.37M | --109.43M | --25.98M |
| Research and development costs | 28.17%29.04M | 7.40%26.18M | 17.53%24.93M | 22.86%91.59M | 31.35%23.35M | 15.86%22.66M | 48.79%24.38M | 1.79%21.21M | -17.59%74.55M | -15.68%17.77M |
| Depreciation amortization depletion | -8.26%19.49M | 0.00%20.11M | 0.86%20.14M | -0.30%82.39M | 1.79%21.07M | 2.90%21.24M | -2.60%20.11M | -3.28%19.97M | 175.53%82.63M | 72.12%20.7M |
| -Depreciation and amortization | -8.26%19.49M | 0.00%20.11M | 0.86%20.14M | -0.30%82.39M | 1.79%21.07M | 2.90%21.24M | -2.60%20.11M | -3.28%19.97M | 175.53%82.63M | 72.12%20.7M |
| Operating profit | 418.47%39.83M | 208.44%18.21M | -220.37%-4.25M | -70.62%13.4M | -40.53%18.99M | 840.79%7.68M | -238.94%-16.8M | 34.08%3.53M | -42.62%45.61M | 342.37%31.93M |
| Net non-operating interest income expense | 134.04%4.1M | 711.52%3.73M | -11.59%3.4M | -45.02%8.04M | 146.40%1.99M | 62.28%1.75M | 2,190.91%460K | -69.89%3.84M | 213.73%14.62M | 119.92%806K |
| Non-operating interest income | 134.04%4.1M | 172.48%3.73M | -36.48%3.4M | -51.81%10.45M | -17.25%1.99M | -37.53%1.75M | -23.38%1.37M | -63.63%5.35M | 105.21%21.69M | 27.19%2.4M |
| Non-operating interest expense | --0 | --0 | --0 | -65.84%2.42M | --0 | --0 | -49.72%910K | -22.50%1.51M | -69.82%7.07M | -73.14%1.59M |
| Other net income (expense) | 122.81%1.02M | 651.27%4.36M | -33.52%1.1M | -3,761.18%-18.67M | -931.32%-19.99M | 193.83%456K | -6.33%-790K | 347.67%1.65M | -92.19%510K | 314.64%2.4M |
| Special income (charges) | 122.81%1.02M | 651.27%4.36M | -33.52%1.1M | -3,761.18%-18.67M | -931.32%-19.99M | 193.83%456K | -6.33%-790K | 347.67%1.65M | -92.19%510K | 314.64%2.4M |
| -Less：Restructuring and merger&acquisition | -122.81%-1.02M | -651.27%-4.36M | 33.52%-1.1M | -197.45%-1.52M | 91.51%-204K | -193.83%-456K | 6.33%790K | -347.67%-1.65M | 92.19%-510K | -314.64%-2.4M |
| -Less:Impairment of capital assets | ---- | ---- | ---- | --20.19M | ---- | ---- | ---- | ---- | --0 | ---- |
| Income before tax | 354.47%44.94M | 253.57%26.3M | -97.31%243K | -95.44%2.77M | -97.18%990K | 2,327.25%9.89M | -251.25%-17.13M | -38.76%9.02M | -16.99%60.74M | 1,613.31%35.14M |
| Income tax | -75.08%6.45M | 139.19%6.39M | 101.50%119K | 4,440.63%1.45M | -101.92%-185K | 1,279.43%25.87M | -571.12%-16.3M | 27.19%-7.93M | -99.84%32K | 2,570.33%9.66M |
| Net income | 340.97%38.5M | 2,496.63%19.92M | -99.27%124K | -97.83%1.32M | -95.39%1.18M | -1,013.44%-15.98M | -110.57%-831K | -33.84%16.95M | 13.64%60.71M | 943.45%25.48M |
| Net income continuous Operations | 340.97%38.5M | 2,496.63%19.92M | -99.27%124K | -97.83%1.32M | -95.39%1.18M | -1,013.44%-15.98M | -110.57%-831K | -33.84%16.95M | 13.64%60.71M | 943.45%25.48M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 340.97%38.5M | 2,496.63%19.92M | -99.27%124K | -97.83%1.32M | -95.39%1.18M | -1,013.44%-15.98M | -110.57%-831K | -33.84%16.95M | 13.64%60.71M | 943.45%25.48M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 340.97%38.5M | 2,496.63%19.92M | -99.27%124K | -97.83%1.32M | -95.39%1.18M | -1,013.44%-15.98M | -110.57%-831K | -33.84%16.95M | 13.64%60.71M | 943.45%25.48M |
| Basic earnings per share | 341.38%0.7 | 1,900.00%0.36 | -99.27%0.0023 | -98.23%0.02 | -96.30%0.0174 | -1,066.67%-0.29 | -113.33%-0.02 | -35.42%0.31 | 11.88%1.13 | 840.00%0.47 |
| Diluted earnings per share | 337.93%0.69 | 1,900.00%0.36 | -99.23%0.0022 | -98.08%0.02 | -95.95%0.0174 | -1,066.67%-0.29 | -114.29%-0.02 | -32.56%0.29 | 6.12%1.04 | 975.00%0.43 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data